Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

BACKGROUND: Capecitabine and irinotecan combination therapy (XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer (mCRC). Recently, in the Association of Medical Oncology of the German Cancer Society (AIO) 0604 trial, tri-weekly XELIRI plus bevacizumab, with reduced...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Chin J Cancer
Auteurs principaux: Kotaka, Masahito, Xu, Ruihua, Muro, Kei, Park, Young Suk, Morita, Satoshi, Iwasa, Satoru, Uetake, Hiroyuki, Nishina, Tomohiro, Nozawa, Hiroaki, Matsumoto, Hiroshi, Yamazaki, Kentaro, Han, Sae-Won, Wang, Wei, Ahn, Joong Bae, Deng, Yanhong, Cho, Sang-Hee, Ba, Yi, Lee, Keun-Wook, Zhang, Tao, Satoh, Taroh, Buyse, Marc E., Ryoo, Baek-Yeol, Shen, Lin, Sakamoto, Junichi, Kim, Tae Won
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5178089/
https://ncbi.nlm.nih.gov/pubmed/28007025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0166-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires